Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Tr
![Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity | Journal for ImmunoTherapy of Cancer Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/1/e000253/F2.large.jpg)
Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity | Journal for ImmunoTherapy of Cancer
![Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/11/e005517/F3.large.jpg)